Pharmacist Suspended After 60,000 Xanax Tablets Left the Legal Medicines Supply Chain Without a Wholesale Licence
Date of Decision: June 17, 2026
Registrant's Role: Pharmacist
Allegations:
- Between September 2024 and June 2025, while acting as the director, superintendent pharmacist and responsible pharmacist of a community pharmacy, the registrant failed to keep approximately 1,080 boxes of Xanax 500 microgram tablets, each containing 60 tablets, within the lawful medicines supply chain.
- During the same period, the registrant supplied approximately 1,080 boxes of Xanax 500 microgram tablets without holding the required Wholesale Distribution Authorisation.
- It was alleged that this conduct amounted to misconduct and impaired the registrant’s fitness to practise.
Outcome: Suspended from the register for six months
GPhC Standards Breached:
- Standard 2 – Pharmacy professionals must work in partnership with others.
- Standard 5 – Pharmacy professionals must use their professional judgement.
- Standard 6 – Pharmacy professionals must behave in a professional manner.
- Standard 9 – Pharmacy professionals must demonstrate leadership.
Case Summary
Allegations
This case concerned the repeated supply of a very large quantity of Xanax from a community pharmacy without the legal authority required for wholesale distribution. The registrant was not acting solely as an employed pharmacist. The registrant was the sole director of the company operating the pharmacy, its superintendent pharmacist and, on a regular basis, its responsible pharmacist. These overlapping roles placed the registrant in a position of substantial professional and organisational responsibility.
Xanax is a brand of alprazolam, a benzodiazepine used primarily in the treatment of anxiety disorders. The determination recorded that alprazolam is a prescription-only medicine, a Class C controlled drug under the Misuse of Drugs Act 1971 and a Schedule 4 controlled drug under the Misuse of Drugs Regulations 2001. The product involved was Xanax 500 microgram tablets supplied in packs of 60. The determination also highlighted the recognised potential for alprazolam misuse and its illicit trade.
Continue Reading the Full Case
Create a free account or log in to access the complete case summary.
- Full allegations considered by the GPhC
- Panel findings and reasoning
- Outcome of the investigation
- Sanctions considered and imposed on the Pharmacist
- Key professional learning points
Original Case Document
View the Full Determination Document
The original determination transcript is available to registered users.
- Download the official GPhC determination
- Full hearing transcript
- Detailed findings of fact
- Sanction reasoning
- Details of the pharmacy professionals involved